, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes. RESULTS: There were approximately 6 million qualifying men with a full year of data. PSA 2018 8. Harms of Prostate -Specific Antigen ( PSA ) screening in prostate cancer : a rapid review Harms of Prostate -Specific Antigen ( PSA ) screening in prostate cancer : a rapid review Harms (...) Prostate cancer screening Top results for prostate cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search

has published a white paper to provide some guidance regarding periprocedural prophylaxis. Since prostate biopsies are also an important part of some active surveillance programs, understanding these risks and communicating them to patients is not only integral to informed consent for prostate cancer screening but also for consideration of treatment options. Once diagnosed with prostate cancer, a man is faced with the risk of overtreatment of indolent disease due to the assumption that diagnosis (...) with a malignancy must necessarily result in treatment of this malignancy. Estimates of overdiagnosis vary widely from less than 5% to more than 75% depending upon the population used with lead times of 5 to 15 years. Although prostate cancer specific mortality and the need for related palliative care is decreased by screening, quality of life may be impaired as a result due to lasting impairment in urinary, bowel, and sexual function. There is considerable distress involved in the decision making process

Prostate cancer screening

imaging (MRI), bone scan, and computed tomography, are often also performed, especially in men presenting with higher risk disease, to check for disease spread. Screening controversy For many reasons, PSA screening remains controversial. Advocates often base their opinions on the European Randomised study of Screening for Prostate Cancer (ERSPC), which suggests that screening may reduce the long term risk of prostate cancer-specific mortality by at least 9% (relative reduction). They also note (...) that substantial observational evidence indicates a reduction in advanced disease and reduction in prostate cancer mortality, which they attribute to the introduction of PSA screening. Opponents of PSA screening highlight the indolent natural course of prostate cancer, citing systematic reviews that reported little or no impact of PSA screening on overall and prostate cancer-specific mortality. Opponents also suggest that the harms and burden from overdiagnosis and overtreatment resulting in unnecessary

PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. The 2012 United States Preventive Services Task Force recommendation against screening for prostate cancer has impacted rates of prostate-specific antigen (PSA) screening and appears to be associated with declining prostate cancer incidence. Our objective was to characterize health care utilization that may explain these observed (...) trends.MarketScan claims, which capture >30 million privately insured patients in the United States, were queried for all men aged 40-64 years for the years 2008-2014. PSA testing, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes.There were approximately 6 million qualifying men with a full year of data. PSA testing, prostate biopsy

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs

for prostate cancer using prostate-specific antigen (PSA) testing. STATEMENT OF THE CLINICAL ISSUE Section: Prostate cancer is the second leading cause of cancer deaths among men in the United States, , with the estimated number of deaths exceeding 28,000 in 2012. The rationale for screening asymptomatic men for prostate cancer in the general population is the potential for reducing mortality rates through early detection of the disease. However, much controversy exists between the potential harms (...) that a patient's age and level of comorbidity need to be considered when deciding whether to screen for prostate cancer. – Assessing risk for prostate cancer has been achieved through development of prostate cancer risk calculators. These factor not only PSA but other risk factors and tumor markers for prostate cancer as well. Rather than using a cutoff value, individual probabilities for any and aggressive prostate cancers are calculated, with the decision for biopsy based on patient and physician views

with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could (...) result in considerable reductions of M+ disease and mortality which if confirmed in larger datasets should trigger further discussion on pros/cons of PCa screening. PATIENT SUMMARY: In a cohort with 19yr of follow-up, we found indications for a more substantial reduction in metastatic disease and cancer-specific mortality in favor of prostate cancer screening than previously reported. If confirmed in larger cohorts, these findings should be considered in the ongoing discussion on harms and benefits

African Americans' Perceptions of Prostate-Specific Antigen Prostate Cancer Screening. In 2012, the U.S. Preventive Services Task Force released a hotly debated recommendation against prostate-specific antigen testing for all men. The present research examines African Americans' beliefs about their susceptibility to prostate cancer (PCa) and the effectiveness of prostate-specific antigen testing in the context of the controversy surrounding this recommendation.This study used a qualitative (...) design to examine perceptions regarding susceptibility and screening. Data were collected at a community health center and three predominantly African American churches in North Carolina. Study participants were 46 African American men and women who attended one of four "listening sessions" for pretesting PCa educational materials (average age = 55 years). Listening sessions of 1.5-hour duration were conducted to pretest materials; while presenting the materials, researchers probed beliefs

of Cancer; Humans; Male; Mass Screening /adverse effects; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5 Email: EDSinfo@hqontario.ca AccessionNumber 32015000712 Date abstract record published 09/06/2015 Health (...) Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms

malignancy that if left untreated would have had a benign or indolent natural history and would have been of no clinical significance). Randomized trials have therefore been conducted. Randomized trials of PSA screening The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial The PLCO Cancer Screening Trial is a multicenter, randomized, two-armed trial designed to evaluate the effect of screening for prostate, lung, colorectal, and ovarian cancers on disease-specific mortality. From 1993 (...) Antigen (PSA) or Digital Rectal Exam (DRE) The evidence is insufficient to determine whether screening for prostate cancer with prostate-specific antigen (PSA) or digital rectal exam (DRE) reduces mortality from prostate cancer. Screening tests are able to detect prostate cancer at an early stage, but it is not clear whether this earlier detection and consequent earlier treatment leads to any change in the natural history and outcome of the disease. Observational evidence shows a trend toward lower

cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third most common cause of cancer-related deaths. Prostate cancer is a heterogeneous disease with a variable natural history ranging from low-risk tumours (unlikely to threaten men’s quality or length of life) to highly aggressive forms. The etiology of PC is largely unknown and the established risk factors—older age, ethnicity, and family history—explain only a fraction of variation in disease occurrence (...) , with the majority of cancers being low risk and organ PSA-Based Population Screening for Prostate Cancer: OHTAC Recommendation. May 2015; pp. 1–5 3 confined. The detection of intermediate-risk tumours was similar in the study groups and, although the detection of high-grade tumours declined with subsequent screening, the progression of PC to metastasis during follow-up did not decline, potentially limiting the effectiveness of screening programs. Overall, although the probability of having a PC detected

Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. To quantify the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.Modelling and validation of the lifetime risk method using publicly available population data.Opportunistic screening for prostate cancer in the Australian population.Australian (...) male population (1982-2012).Prostate-specific antigen testing for prostate cancer screening.Primary: lifetime risk of overdiagnosis in 2012 (excess lifetime cancer risk adjusted for changing competing mortality); Secondary: lifetime risk of prostate cancer diagnosis (unadjusted and adjusted for competing mortality); Excess lifetime risk of prostate cancer diagnosis (for all years subsequent to 1982).The lifetime risk of being diagnosed with prostate cancer increased from 6.1% in 1982 (1 in 17

Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening. Prostate cancer screening reduces advanced disease and prostate cancer death but is controversial due to downstream harms including unnecessary biopsies and overtreatment. In 2012 the United States Preventive Services Task Force (USPSTF) recommended against screening men for prostate cancer, a practice common since the early 1990's. This dramatic policy change was opposed by many

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality.To determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended.This multicentre population-based randomised (...) significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level.In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.Copyright © 2019. Published by Elsevier B.V.

Canadian Urological Association recommendations on prostate cancer screening and early diagnosis CUAJ • October 2017 • Volume 11, Issue 10 © 2017 Canadian Urological Association CUA GUIDELINE 298 Cite as: Can Urol Assoc J 2017;11(10):298-309. http://dx.doi.org/10.5489/cuaj.4888 See related editorial on page 295 Introduction Prostate cancer remains the most commonly diagnosed non- cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In 2016 (...) , an estimated 21 600 men were diagnosed with prostate cancer and 4000 men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over- treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostate cancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic.Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313

and preferences. Through this project, Dr. Dobbins and her research team will explore whether the use of patient decision aids with high-quality and user-friendly summaries of research evidence, or summaries of research evidence alone, help to improve the quality of decision making by men facing prostate cancer screening decisions. Condition or disease Intervention/treatment Phase Prostate Cancer Other: Evidence-based information Other: Patient Decision Aid Other: Sham information Not Applicable Detailed (...) Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

sources were arguing that screening would have a big impact on metastatic disease, then I think you had an obligation to analyze that claim against what the numbers actually show. Of course, you did provide that context further down in the piece … “the survival rate for early-stage prostate cancer is 99 percent after 10 years, regardless of whether a man opted for surgery, radiation or active monitoring” … “the balance of benefits and harms is still close” … “This is not a recommendation that says men (...) Is PSA now “OK”? What the task force really said about the evidence on prostate cancer screening Is PSA now "OK"? What the task force really said about the evidence on prostate cancer screening - HealthNewsReview.org Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain

Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication. Shared patient-physician decision-making regarding treatment for prostate cancer detected by prostate-specific antigen screening involves a complex calculus weighing the risk of the cancer and patient life expectancy. We investigated quantifying these competing risks using the probability that the cancer was "overdiagnosed"-i.e., would not have been (...) clinically diagnosed (diagnosed without screening) during the patient's remaining lifetime.Using an established model of prostate cancer screening and clinical diagnosis, we simulated screen-detected cases and determined whether modeled clinical diagnosis would occur before non-cancer death, which was based on comorbidity-adjusted population lifetables. Logistic regression models were fitted to the simulated data and used to estimate overdiagnosis probabilities given patient age, PSA level, Gleason sum